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During our studies on mutant strains of the rifamycin producer Nocardia mediterranea, we isolated a morphological variant which produced a mixture of novel ansamycins. We report the structure elucidation of the major component, rifamycin Z, together with its proposed biogenetic relationship with the ansamycins so far reported.
Structure Determination
Evidence for the structure of rifamycin Z (I) was obtained by comparing analytical and spectroscopic properties with those previously reported for rifamycin W1) (II). Elemental analyses and a molecular ion in a EI mass spectrum at m/z=651, as well as 1H and 13C NMR spectral data indicate I has a molecular formula C35H41NO11, i.e. I contains four hydrogens less than II (C35H45NO11). The UV-VIS spectrum of I in pH 7.38 buffer solution [;max, nm (s): 292 (21,700), 348 (10,800), 430 (sh), 550 (2,300)] is the same as that of II, indicating that the naphthoquinone chromophores in I and II are identical. This is confirmed by the mass spectrum of I, which shows a similar pattern of fragmentation of the chromophore as that of II, i.e. fragments at m/z=286, 274, 273, 258 and 246. The mass fragmentation attributable of the ansa chain indicated a loss of two molecules of water instead of four as in II2) , thus suggesting that the structural difference between I and II is in the ansa chain.
One ionizable function with pKa 4.9 can be spectrophotometrically detected for I in aqueous solution. By potentiometric titration in methylcellosolve-H2O (4: 1), a pKa 6.1 is obtained. These observations indicate that the same acidic function exists on the chromophore of I as in II. Rifamycin Z is unstable in basic solution.
The IR spectrum of I in CDC13 solution as compared with that ofII1, 3) has two additional bands [1730 (vc=o) and 1250 (vc-o-c) cm-1] assignable to a lactone group. Also, the different absorption of the OH groups in the ansa chain, in particular vOH-3600 cm-1, is related to a different hydrogen bonding, suggesting a different conformation of the ansa chain.
The 1H NMR data of rifamycin Z (I) are reported in Table 1 . When the data of I are compared with those of II1), it is evident that the former lack the AB system at d 3.78 and 4.08 ppm, due to CH2OH-34a and the paramagnetic shift at H-25. Since all the other protons show a similar data, the main structural variations must occur at C-34a and C-25. The different Jvlc values from H-23 to H-27 indicate that the conformation of the ansa chain in I is quite different from that in II, as may be expected from the lactonization of the COOH-34a with the OH-25. This difference in conformation is also reflected by the diamagnetic shift of nearly all the protons of I with respect to II; in fact, different aromatic solvent in- The absolute configuration of C-25, C-26 and C-27 is that reported for rifamycin B5), while that of C-28 is assumed R according to the biogenetic pattern described by BRUFANI et al. for ansamycins6). It is quite interesting to point out that the relative configuration of the protons of the ring matches that deduceable from the vicinal coupling constants of the protons H-28, H-27, H-26 and H-25 (see Table 1 ).
In fact, J27,28=1.5, J26,27=4 and J25,26=11.5 correspond to a diequatorial, axial-equatorial and diaxial interactions, respectively, of the concerning protons.
Biosynthesis
We propose that rifamycin Z derives biosynthetically from rifamycin W by the oxidation of the hydroxymethyl group C-34a to a carboxyl which then lactonizes with the hydroxyl at C-25. The same relationship probably exists between streptovaricin G and F7) and between protorifamycin I lactone and OCT. 1981 protorifamycin I8). A biogenetic relationship between the known ansamycins has been recently reported by GHISALBA et al.8).
In our opinion rifamycin Z has its counterpart in the protorifamycin I lactone, thus confirming the hypothesis that rifamycins and 8-deoxyansamycins follow two parallel biosynthetic pathways.
Biological Activity
Rifamycin Z shows no activity against Gram-positive bacteria, Gram-negative bacteria and Mycobacterium tuberculosis.
Experimental UV-VIS spectra were measured on a Perkin-Elmer 4000 and IR spectra on a Perkin-Elmer 580 spectrometer. Mass spectra were obtained in direct inlet system at 70 eV on a Hitachi-Perkin Elmer RMU-6L spectrometer. 1H NMR spectra and data at 270 MHz and 13C NMR spectra and data at 67.88 MHz were determined on a Bruker WH-270 FT NMR cryospectrometer equipped with a 36 K BNC-12 computer and a disk unit. Solvents used were pyridine-d5 and acetone-d6 -DMSO-d6 with TMS as the internal reference. Analytical TLC's were carried out on silica gel (Merck HF254) plates using CHCI3 -MeOH (9: 1) as the mobile phase.
Column chromatography was performed with 0.05 -0.20 mm silica gel (Merck).
Occurrence and Isolation of Rifamycin Z Mutant S/725 is a morphological variant of N. mediterranea strain ME/291 obtained by mutation of spores with nitrosoguanidine (conditions as in Ref. 9). Rifamycin Z was produced by fermentation of the above mutant in a complex organic medium10) for 168 hours at 28°C. Fermentation broths were filtered, adjusted to pH 2.0 and extracted with ethyl acetate; the crude material obtained was purified by a countercurrent distribution of 180 transfers with benzene -methanol -0.01 N HCl -hexane (3: 2: 1: 1) as solvent system. The appropriate fractions containing rifamycin Z were pooled, concentrated and purified by column chromatography, with CHCl3 -MeOH (95: 5) as eluent. Yellow crystals of pure rifamycin Z were obtained from ethyl acetate, m.p. 253-255°C (dec.). Rf under the above condition was 0.32.
